A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
Authors
Keywords
Trastuzumab, Lapatinib, Bevacizumab, HER2, VEGF
Journal
INVESTIGATIONAL NEW DRUGS
Volume 33, Issue 1, Pages 177-186
Publisher
Springer Nature
Online
2014-10-17
DOI
10.1007/s10637-014-0173-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal
- (2015) Filip Janku et al. Oncotarget
- HER2 aberrations in cancer: Implications for therapy
- (2014) Min Yan et al. CANCER TREATMENT REVIEWS
- Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer†
- (2013) G. S. Falchook et al. ANNALS OF ONCOLOGY
- Human epidermal receptor 2-amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment
- (2013) Gerald S. Falchook et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment
- (2013) Gerald S. Falchook et al. Journal of Thoracic Oncology
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
- (2012) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases
- (2012) D. P. Kodack et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
- (2011) Hope S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
- (2010) Ymera Pignochino et al. BMC CANCER
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HER2 Polymorphisms and Breast Cancer in Tunisian Women
- (2009) Imen Kallel et al. Genetic Testing and Molecular Biomarkers
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity
- (2008) Zhang Weihua et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search